McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution

Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures, along with its significantly enhanced electronic patient reported outcome (ePRO) module.

“McKesson Ventures is excited to invest in Clinical Ink, a market leader in clinical trial enablement technology,” said Dave Schulte, McKesson Ventures senior vice president and managing director. “Clinical Ink’s innovative eSource solutions are particularly well-positioned as the industry shifts to more decentralized trials and remote monitoring.”

Lunexis™ ePRO+ is part of a unified technology platform that streamlines implementation processes and allows patients and sites to choose how they want to participate in the study—smartphone, tablet, or web. Lunexis ePRO+ allows sites and patients to have unprecedented flexibility to choose the technology option that makes the most sense for them.

Clinical trial sponsors can now choose deployment modalities to suit their protocols and patients, rather than having the technology drive the selection. Although this suggests a higher degree of complexity in terms of implementation, ePRO+ still supports the rapid system implementation Clinical Ink is known for, with study builds now less than 30 days, including translations.

Lunexis ePRO+ is part of an eSource ecosystem that simplifies sponsors’ and contract research organizations’ real-time data collection workflows, which enables study teams to confidently make critical decisions. Thus, sponsors stand to gain higher quality data as more actively engaged patients and sites enter information more efficiently according to protocol.

TransPerfect Translations has partnered with Clinical Ink to reimagine and simplify the complex translation process. The partnership alleviates the inefficiencies in the translation feedback process and condenses the typical ePRO translation workflow and timeline.

“As the eSource pioneers with tens of thousands of site-user interactions behind us, we know our solutions must be adaptable to patients’ and sites’ day-to-day realities,” said Clinical Ink CEO Ed Seguine. “A unified, flexible, patient-centric solution helps patients consistently contribute the data that sponsors need, giving confidence in the data integrity, whatever the trial design. McKesson Ventures’ investment further validates the need for, and opportunity represented by, these technologies.”

Read the full press release here.